Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Current Deferred Revenue (2016 - 2025)

Capricor Therapeutics (CAPR) has 8 years of Current Deferred Revenue data on record, last reported at $12.0 million in Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 8.61% year-over-year to $12.0 million; the TTM value through Sep 2025 reached $12.0 million, down 8.61%, while the annual FY2024 figure was $12.0 million, 50.56% down from the prior year.
  • Current Deferred Revenue reached $12.0 million in Q3 2025 per CAPR's latest filing, roughly flat from $12.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $40.0 million in Q1 2022 and bottomed at $12.0 million in Q4 2024.
  • Average Current Deferred Revenue over 4 years is $19.9 million, with a median of $18.0 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: soared 86.7% in 2023, then tumbled 50.56% in 2024.
  • A 4-year view of Current Deferred Revenue shows it stood at $18.0 million in 2022, then skyrocketed by 34.98% to $24.3 million in 2023, then plummeted by 50.56% to $12.0 million in 2024, then changed by 0.0% to $12.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $12.0 million in Q3 2025, $12.0 million in Q2 2025, and $12.0 million in Q1 2025.